Case report: Supreme Court hears generics battle against brands
The US Supreme Court today considered arguments in a debate that promises to provide guidance on what role regulatory agencies can be expected to play in patent decisions, and how patent attorneys should interact with such agencies
The case centres on how much patent information brand drug manufacturers must disclose to the Food and Drug Administration.
The questions asked by the justices in Caraco Pharmaceutical Laboratories, Ltd v Novo Nordisk centred both on congressional intent in its...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.